ALSO NOTED: FDA accepts Tarceva sNDA; Verus licenses Twinject; StemCells gains stake in ReNeuron; and much more...

> The FDA has accepted OSI Pharmaceuticals' supplemental NDA for Tarceva -- with chemotherapy -- to treat pancreatic cancer. The FDA has six months to make a decision. Article

> San Diego-based Verus has licensed Twinject from Hollister-Stier Laboratories. Twinject -- approved by the FDA in 2003 -- is a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions. Release

> StemCells has licensed its method for handling human neural stem cells to ReNeuron in exchange for a stake in the company. Story

> A judge has turned down Merck's bid for a two-month delay in the first trial over Vioxx, rejecting the drug giant's argument that news of the Texas attorney general's suit against Merck made it impossible to obtain a fair hearing of the issue. Story

> Schering-Plough has opened commercial operations in Pakistan and Korea. Release

> The standard test for prostate cancer is inaccurate and a poor tool for determining if men are cancer free, according to researchers. Article

> Toronto-based Lorus Therapeutics has wrapped a Phase III trial of Virulizin for pancreatic cancer. Results are expected in late 2005. Release

> Astellas has terminated a deal with QLT regarding the licensing and supply of the acne treatment Aczone in North America. Report

> West Pharmaceuticals is buying Medimop Medical Products, which makes devices for injectable drugs, for $40 million. Report

> In order to enhance the independence of Mylan's board of directors, two senior executives have resigned their posts on the board, leaving nine members. Article

And Finally... Health officials in the UK have produced a cancer "map" of the country, showing how high levels of smoking and drinking in some communities have triggered higher concentrations of the disease. Article

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.